Primary cell assays

Our extensive portfolio of disease models 

In addition to immortalised or transformed cell lines, we offer induced pluripotent stem cell (iPSC)-derived and primary cell models. Our portfolio covers various disease paradigms, including fibrosis, metabolic disorders and tissue regeneration. Cells are sourced from healthy donors or patients with the disease of interest. We provide, amongst others, fibroblasts, endothelial cells, hepatocytes and purified immune cells from peripheral blood or ex vivo whole blood assays. We also utilise complex tissues from mice and rats for ex vivo disease modelling.  

Primary cell assays – examples 

• Fibrosis-induction assay in primary human fibroblasts from diverse origins, measuring activation of αSMA, CTGF, periostin, and additional markers  at RNA and protein levels 
• Scratch (migration) assay in primary human fibroblasts and primary smooth muscle cells, utilising automated scratch IncuCyte for real-time imaging and analysis 
• Primary human endothelial cells (EC) 
• Impedance-based EC permeability assay for assessing endothelial dysfunction 
• Transendothelial migration (TEM) assay 
• Angiogenesis/tube formation assay 
• Migration assays.

In the area of immune cells and inflammation, we provide a wide range of immune cell assays based on isolated human immune cell populations and ex vivo whole blood for inflammation and immune-oncology research. Examples include: 

• Immune cell differentiation (e.g., Treg, Th17, monocytes, macrophages)
• Cytokine production and profiling
• FACS profiling
• Immune cell metabolism
• Phagocytosis
• Oxidative burst
• Mixed lymphocyte reaction
• Cell killing assays
• Antibody-dependent cellular cytotoxicity (ADCC).

Precision-cut tissue slices (PCTS) 

PCTS offer a technology that bridges the in vivo and in vitro realms. Derived from typically healthy animals, PCTS maintain organ complexity under cell culture conditions. Disease phenotypes, such as fibrosis in liver slices, can be induced and treated ex vivo, enabling early evaluation of a compound’s antifibrotic activity and providing potential proof of principle in a streamlined, PK-independent manner. Fibrosis markers can be monitored over time using RT-PCR, ELISA or histological techniques.